Guest Editors
Dr. Hitesh Vasiyani
Email: hiteshvasiyani@yahoo.com
Affiliation: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA-23284, USA.
Homepage:
Research Interests: Immuno oncology, novel drug discovery, breast cancer
Summary
KRAS mutations are among the most frequently occurring oncogenic alterations in solid tumors, particularly in pancreatic, lung, and colorectal cancers. These mutations are strongly associated with aggressive disease progression, therapeutic resistance, and poor clinical outcomes. Despite the development of selective KRAS inhibitors—such as those targeting KRAS G12C, G12D durable responses have been limited, and resistance often emerges rapidly due to pathway redundancy and tumor heterogeneity.
This special issue aims to highlight recent advances and ongoing challenges in understanding KRAS-driven oncogenesis and therapeutic targeting. Emphasis will be placed on mechanistic studies of RAS signaling, resistance pathways, and tumor microenvironment interactions. Additionally, the issue will explore innovative combinatorial strategies, including dual-targeting approaches with kinase inhibitors, immune checkpoint blockade, or metabolic modulators. We invite original research, reviews, and perspectives that provide insight into KRAS biology and pave the way for more effective, long-term treatment strategies for KRAS-mutant cancers.
Keywords
KRAS mutations, oncogenic RAS signaling, targeted therapy resistance, KRAS G12C / G12D inhibitors, tumor heterogeneity, combinatorial cancer therapy, immune checkpoint blockade, tumor microenvironment, RAS-driven oncogenesis
Login
Register
Submit a Paper
Propose a Special lssue